Baxalta Gmbh

Baxter International Inc.

Baxter Healthcare Sa

Ology Bioservices Inc.

P Noel Barrett

Hartmut Ehrlich

Thomas R Kreil

Falko-Günter Falkner

Birgit Schafer

Annett Hessel

Ian Livey

Brian A Crowe

Nina Wressnigg

Gerald Aichinger

Birgit Schäfer

The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.

Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses

The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety ofgenospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Compositions comprising chimeric OSPA molecules and methods of use thereof

Growing community of inventors

Klosterneuburg/Weidling, Austria

P Noel Barrett